Sullivan Christopher Ryan 4
4 · Avalo Therapeutics, Inc. · Filed Dec 14, 2021
Insider Transaction Report
Form 4
Sullivan Christopher Ryan
Chief Financial Officer
Transactions
- Purchase
Common Stock
2021-12-10$1.57/sh+955$1,499→ 9,004 total
Footnotes (1)
- [F1]These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan.